Insitro: $2B valuation, IPO Readiness 65, Series D. Machine learning-driven drug discovery company using large-scale data generation and AI to identify new therap. Track live on The IPO Stack.
Machine learning-driven drug discovery company using large-scale data generation and AI to identify new therapeutics.
Scores, valuations, and IPO signals for the companies that matter. 5-minute read, every Tuesday.
Top companies most likely to IPO in 2026, ranked by IPO Readiness Score.
Track Insitro IPO timeline, funding rounds, investor activity, and valuation on TechStackIPO — the pre-IPO intelligence platform.
Insitro has not publicly announced IPO plans. Track TechStackIPO for the latest signals and subscribe to The IPO Stack for weekly updates.
Insitro is valued at $2B as of the most recent funding round. This valuation is based on its most recent private funding round tracked by TechStackIPO.
Accredited investors can access Insitro shares through secondary market platforms, pre-IPO investment funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace tracks available access options. Note: pre-IPO investments carry higher risk and limited liquidity compared to public market investing.
Insitro scores 65/100 (Grade: C) on TechStackIPO's IPO Readiness Index. The score evaluates funding scale, valuation trajectory, funding momentum, stage progression, and company maturity. Scores above 70 indicate strong near-term IPO potential.
Insitro has raised $993M in total venture capital and private equity funding, with backing from SoftBank Vision Fund 2, a16z Bio, a16z.
Insitro's notable investors include SoftBank Vision Fund 2, a16z Bio, a16z, Third Rock Ventures. Full investor details, funding round history, and lead investor breakdowns are available on TechStackIPO.
Insitro is a Biotechnology company. Machine learning-driven drug discovery company using large-scale data generation and AI to identify new therapeutics.